middle.news
Orthocell Scores First US Sales for Remplir™ Nerve Repair Product
9:11am on Thursday 10th of July, 2025 AEST
•
Healthcare
Read Story
Orthocell Scores First US Sales for Remplir™ Nerve Repair Product
9:11am on Thursday 10th of July, 2025 AEST
Key Points
First US sales revenue recorded for Remplir™ following FDA 510(k) clearance
Initial surgeries performed in Ohio and Florida via specialist distributors
Order fulfillment and invoicing processes validated with logistics partner Uniphar
Orthocell targets US$1.6 billion nerve repair market with growth expected in H2 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Orthocell (ASX:OCC)
OPEN ARTICLE